The impact of center accreditation on hematopoietic cell transplantation (HCT)

被引:0
|
作者
S Marmor
J W Begun
J Abraham
B A Virnig
机构
[1] School of Medicine,Division of Health Policy & Management
[2] University of Minnesota,undefined
[3] School of Public Health,undefined
[4] University of Minnesota,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
There are two voluntary center-accrediting organizations in the USA, the Foundation for the Accreditation of Cellular Therapy (FACT) and core Clinical Trial Network (CTN) certification, that are thought to improve and ensure hematopoietic cell transplantation (HCT) center quality care and certify clinical excellence. We sought to observe whether there are differences in outcomes between HLA-matched and -mismatched HCT by CTN and FACT status. Using the 2008–2010 Center for International Blood & Marrow Transplant Research data we created three center categories: non-FACT centers (24 centers), FACT-only certified centers (106 centers) and FACT and core clinical trial network (FACT/CTN) certified centers (32 centers). We identified patient characteristics within these centers and the relationship between FACT certification and survival. Our cohort consisted of 12 993 transplants conducted in 162 centers. After adjusting for patient and center characteristics we found that FACT/CTN centers had consistently superior results relative to non-FACT and FACT-only centers (P<0.05) especially for more complex HCT. However, non-FACT centers were comparable to FACT-only centers for matched related and unrelated patients. Although FACT status is an important standard of quality control that begins to define improved OS, our results indicate that FACT status alone is not an indicator for superior outcomes.
引用
收藏
页码:87 / 94
页数:7
相关论文
共 50 条
  • [41] Performance status, but not the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI), predicts mortality at a Canadian transplant center
    R Guilfoyle
    A Demers
    C Bredeson
    E Richardson
    M Rubinger
    D Szwajcer
    M D Seftel
    Bone Marrow Transplantation, 2009, 43 : 133 - 139
  • [42] JACIE ACCREDITATION STATUS AND OUTCOME AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Chabannon, C.
    Gratwohl, A.
    Brand, R.
    McGrath, E.
    van Biezen, A.
    Sureda, A.
    Baldomero, H.
    Ljungman, P.
    Apperley, J.
    Rambaldi, A.
    CYTOTHERAPY, 2014, 16 (04) : S11 - S11
  • [43] Referral to Transplant Center for Hematopoietic Cell Transplantation
    Majhail, Navneet S.
    Jagasia, Madan
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 28 (06) : 1201 - +
  • [44] Performance status, but not the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI), predicts mortality at a Canadian transplant center
    Guilfoyle, R.
    Demers, A.
    Bredeson, C.
    Richardson, E.
    Rubinger, M.
    Szwajcer, D.
    Seftel, M. D.
    BONE MARROW TRANSPLANTATION, 2009, 43 (02) : 133 - 139
  • [45] Impact of prior therapy with imatinib mesylate on the outcome of hematopoietic cell transplantation (HCT) for chronic myeloiod leukemia (CML)
    Lee, Stephanie
    Maziarz, Richard
    Kukreja, Manisha
    Wang, Tao
    Giralt, Sergio
    Szer, Jeffrey
    Woolfrey, Ann
    Arora, Mukta
    BLOOD, 2007, 110 (11) : 227A - 227A
  • [46] Impact of Pretransplant Respiratory Virus Detection through Universal Screening in Children Undergoing Hematopoietic Cell Transplantation (HCT)
    Kim, Yae-Jean
    Waghmare, Alpana
    Kuypers, Jane M.
    Jerome, Keith R.
    Pergam, Steven A.
    Xie, Hu
    Leisenring, Wendy M.
    Ogimi, Chikara
    Boeckh, Michael J.
    Englund, Janet A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S179 - S180
  • [47] HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FOR SEVERE APLASTIC ANEMIA (SAA): IMPACT OF GRAFT SOURCE AND ECONOMIC REGIONS.
    Kumar, R.
    Pasquini, M.
    Klein, J.
    Bonflm, C.
    Aljurf, M.
    Saber, W.
    Rowlings, P.
    Inamoto, Y.
    Szer, J.
    Kuwatsuka, Y.
    Hu, Z.
    Gupta, V.
    Seftel, M.
    Atsuta, Y.
    Kimura, F.
    HAEMATOLOGICA, 2013, 98 : 253 - 253
  • [48] Effect of T cell apoptosis on lymphopenia following allogeneic hematopoietic cell transplantation (HCT).
    Lin, MT
    Frangoul, H
    Tseng, LH
    Gooley, T
    Singleton, KL
    Barsoukov, A
    Akatsuka, Y
    Hansen, JA
    BLOOD, 1999, 94 (10) : 155A - 155A
  • [49] Impact of Fluoroquinolone Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation; Single Center Experience
    Al-Shaibani, Eshrak
    Evans, Zoe
    Madsen, Kayla
    Chen, Shiyi
    Chen, Carol
    Pasic, Ivan
    Lam, Wilson
    Law, Arjun
    Michelis, Fotios V.
    Gerbitz, Armin
    Kim, Dennis D.
    Kumar, Rajat
    Lipton, Jeffrey H.
    Mattson, Jonas
    Husain, Shahid
    Al-Shaibani, Zeyad
    Viswabandya, Auro
    BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 99 - 99
  • [50] Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
    Sorror, ML
    Maris, MB
    Storb, R
    Baron, F
    Sandmaier, BM
    Maloney, DG
    Storer, B
    BLOOD, 2005, 106 (08) : 2912 - 2919